Cancer biotherapy最新文献

In vivo distribution of integrins in renal cell carcinoma: integrin-phenotype alteration in different degrees of tumor differentiation and VLA-2 involvement in tumor metastasis. 肾细胞癌中整合素的体内分布:整合素在不同程度肿瘤分化中的表型改变及vas -2在肿瘤转移中的参与。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.287

G Anastassiou, S Duensing, G Steinhoff, H Kirchner, A Ganser, J Atzpodien

引用次数: 12

Saffron chemoprevention in biology and medicine: a review. 藏红花化学预防在生物学和医学上的研究进展。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.257

S C Nair, S K Kurumboor, J H Hasegawa

{"title":"Saffron chemoprevention in biology and medicine: a review.","authors":"S C Nair, S K Kurumboor, J H Hasegawa","doi":"10.1089/cbr.1995.10.257","DOIUrl":"https://doi.org/10.1089/cbr.1995.10.257","url":null,"abstract":"A growing body of evidence indicate that carotenoids possess anticarcinogenic, anti-mutagenic and immunomodulating effects. Saffron obtained from the dried stigmas of Crocus sativus L., is an important spice, rich in carotenoids, consumed commonly in different parts of the world. Our laboratory first reported the anticancer activity of saffron extract (dimethyl-crocetin) against a wide spectrum of murine tumors and human leukemia cell lines. The present report reviews the role of saffron in serving as a chemopreventive agent in modifying cancer risk. Dose-dependent cytotoxic effect to carcinoma, sarcoma and leukemia cells in vitro were noted. Saffron delayed ascites tumor growth and increased the life span of the treated mice compared to untreated controls by 45-120%. In addition, it delayed the onset of papilloma growth, decreased incidence of squamous cell carcinoma and soft tissue sarcoma in treated mice. Understanding the mechanisms of action of saffron have been solitarily based on their carotenoid-like action. Our results indicated significant inhibition in the synthesis of nucleic acids but not protein synthesis. It appears now that saffron (dimethyl-crocetin) disrupts DNA-protein interactions e.g. topoisomerases II, important for cellular DNA synthesis.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"10 4","pages":"257-64"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1995.10.257","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19570527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 203

Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. 干扰素α -2a和外束放疗在胶质瘤患者初始治疗中的应用:国家生物治疗研究组的一项试点研究

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.265

R O Dillman, M Wiemann, R K Oldham, G Soori, M Bury, R Hafer, C Church, C DePriest

{"title":"Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group.","authors":"R O Dillman, M Wiemann, R K Oldham, G Soori, M Bury, R Hafer, C Church, C DePriest","doi":"10.1089/cbr.1995.10.265","DOIUrl":"https://doi.org/10.1089/cbr.1995.10.265","url":null,"abstract":"The National Biotherapy Study Group conducted a phase I/II trial of alpha-interferon (IFN) plus radiation therapy (RT) in glioma patients to confirm the feasibility of combining these two modalities. Patients newly diagnosed gliomasreceived external beam RT as 180 cGy in 33 fractions over six to seven weeks, five days a week, and IFN at a dose of 3 MIU SC Monday, Wednesday and Friday of each week. IFN was increased to 5 MIU after two weeks and was given for up to 16 weeks. Patients were monitored for toxicity and failure-free and overall survival. There were 12 men and seven women with an age range of 24-77, and a median age of 64 years. There were 12 glioblastomas and seven advanced astrocytomas. Complete surgical resection was carried out in two patients, nine had a partial resection, and eight had a biopsy only. Two patients in the latter group deteriorated rapidly and received < 2 weeks of RT/IFN. One patient stopped IFN because of a skin rash, another stopped because of concurrent pneumonia, and one patient was noncompliant. RT and IFN were well-tolerated; 14 of the 19 patients completed the eight weeks of IFN/RT. However, only three patients took IFN for the maximum of 16 weeks. The only grade 4 toxicities noted were increases SGOT in three, increases alk phos in two, and severe fatigue in four patients. The median failure-free survival was two months, median survival was 7.5 months, and four patients survived beyond one year. The longest survivor was 29.1 months, and one patient is still alive after 20.7 months. IFN/RT can be safely co-administered in patients with gliomas. A randomized trial would be needed to establish clinical benefit.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"10 4","pages":"265-71"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1995.10.265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19570529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Inhibition of the growth of a murine and various human tumor cell lines in culture and in mice by mixture of certain substances of the circulatory system. 通过循环系统中某些物质的混合物抑制培养物和小鼠体内小鼠和各种人类肿瘤细胞系的生长

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.157

G Kulcsár

{"title":"Inhibition of the growth of a murine and various human tumor cell lines in culture and in mice by mixture of certain substances of the circulatory system.","authors":"G Kulcsár","doi":"10.1089/cbr.1995.10.157","DOIUrl":"https://doi.org/10.1089/cbr.1995.10.157","url":null,"abstract":"It is well documented that despite global abnormalities of the immune system in AIDS and other immune deficiency diseases or in immunosuppressed patients, the incidence of only a few kinds of tumor increases, and that the degree of immunosuppression seems not to be a critical factor in the development of even these tumors. The fact that tumors do not develop in the majority of population during their lifetime, despite the ineffectiveness of the known immune system against the majority of tumors, can only be explained by hypothesizing that the living system has an additional defense mechanism against tumors. On the bases of literary data, it can be assumed that the effective agents of this defense mechanism are certain substances of the circulatory system. We proved this hypothesis by being able to select thirteen substances of the circulatory system from 71 compounds tested, using the synergistic tumor cell-killing effect as criteria. The mixture containing the thirteen substances (L-tryptophan, L-tyrosine, L-methionine, L(-)-malate, L-ascorbate, L-arginine, L-phenylalanine, L-histidine, 2-deoxy-D-ribose, d-biotin, pyridoxine, adenine and riboflavin) had a cytotoxic effect against Sp2/0-Ag14 mouse and K562, HEp-2, HeLa and Caco-2 human tumor cell lines in well-controlled conditions, but it was not cytotoxic against Vero normal cell line. The mixture of the above substances increased significantly the survival time of mice (T/C% 148.1) injected i.p. with Sp2/0-Ag14 mouse myeloma cells by killing more than 2 logs (99%) of the cells. Approximately the same 2 logs cell kill was found counting the Sp2/0-Ag14 cells in the ascitic fluid of control and treated animals after finishing treatment. The above mixture slowed down the growth of HeLa solid tumor significantly (T/C%, the least value 35.7). The weight loss of control and treated group during treatment did not differ significantly.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"10 2","pages":"157-76"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1995.10.157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18667883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Cancer biotherapy: the field matures. 癌症生物治疗:该领域日趋成熟。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.91

R K Oldham

引用次数: 0

Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon. 白细胞介素- 2联合干扰素治疗癌症患者的糖尿病。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.45

R P Whitehead, A Hauschild, E Christophers, R Figlin

引用次数: 21

Cancer clinical trials in the community setting: a 20 year retrospective. 社区环境中的癌症临床试验:20年回顾。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.95

R A Avent, R O Dillman

引用次数: 6

Combination therapy with traditional Chinese medicines and Streptococcus pyogenes products (OK 432) for endogenous tumor necrosis factor therapy. A preliminary report. 中药与化脓性链球菌产品(OK 432)联合治疗内源性肿瘤坏死因子。初步报告。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.131

K Haranaka, A Sakurai, N Satomi, T Ono, R Haranaka

{"title":"Combination therapy with traditional Chinese medicines and Streptococcus pyogenes products (OK 432) for endogenous tumor necrosis factor therapy. A preliminary report.","authors":"K Haranaka, A Sakurai, N Satomi, T Ono, R Haranaka","doi":"10.1089/cbr.1995.10.131","DOIUrl":"https://doi.org/10.1089/cbr.1995.10.131","url":null,"abstract":"The antitumor activity of combination therapy with traditional Chinese medicines and OK432 (Streptococcus pyogenes) for cancer patients was investigated. Excellent antitumor activity of this treatment was achieved in one patient with hepatocellular carcinoma. The present report describes the clinical course of this patient and examines the contribution of production of tumor necrosis factor (TNF) and interferon-gamma (IFN). Endogenous production of TNF could be observed after drip intravenous injection of OK 432 in the serum of patients treated by previous oral administration of traditional Chinese medicines. The serum levels of IFN were very low and remained at almost undetectable levels under these conditions. The selective use of immunostimulants such as traditional Chinese medicines may be of value in combination with other therapies such as drip infusion of OK 432, in the treatment of advanced cancer or of aged patients because of the low toxicity. One patient out of 12 revealed a partial response as assessed by the antitumor activity. However, with this treatment, patients did become free from pain and a good performance status was supported.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"10 2","pages":"131-8"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1995.10.131","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18667920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Correlation between malignancy level of AKR lymphoma variants and sensitivity to hyperthermia. AKR淋巴瘤变异体恶性程度与热疗敏感性的相关性。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.53

J Leibovici, G Klorin, O Klein, M Michowitz

{"title":"Correlation between malignancy level of AKR lymphoma variants and sensitivity to hyperthermia.","authors":"J Leibovici, G Klorin, O Klein, M Michowitz","doi":"10.1089/cbr.1995.10.53","DOIUrl":"https://doi.org/10.1089/cbr.1995.10.53","url":null,"abstract":"The tumor progression process has been found to be accompanied by various cell membrane modifications. This cell organelle may therefore be considered as a target for drugs directed against tumor cells of advanced cancer. Hyperthermia acts on tumor cells largely, although not only, via an effect on the cell membrane. In the present study, the in vitro effect of hyperthermia on the tumorigenicity of cells derived from two AKR lymphoma variants of malignancy, TAU-39 of low (LM) and TAU-38 of high-malignancy (HM), was compared. The cells of the HM variant were markedly more sensitive to hyperthermic treatment than those of the LM one. Pretreatment of cells at 41 degrees C or 43 degrees C resulted in a more marked delay in tumor appearance in mice injected with the HM than in those inoculated with the LM variant. Moreover, in mice inoculated with cells pretreated at 45 degrees C, long term survivors were found only in those inoculated with the HM variant. These results corroborate our previous data regarding the effect of hyperthermia on metastatic and primary tumor cells of AKR lymphoma as well as the F1 and F10 variants of B16 melanoma.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"10 1","pages":"53-60"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1995.10.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18783202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Whither magic bullets and guided missiles: monoclonal antibodies 20 years later. 去往何处的魔弹和导弹:20年后的单克隆抗体。

Cancer biotherapy Pub Date : 1995-01-01 DOI: 10.1089/cbr.1995.10.177

R O Dillman

引用次数: 6